Kenvue Inc. (NYSE:KVUE) Shares Acquired by Stonegate Investment Group LLC

Stonegate Investment Group LLC increased its position in Kenvue Inc. (NYSE:KVUE) by 1.2% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,232,340 shares of the company’s stock after acquiring an additional 26,985 shares during the period. Kenvue makes up about 1.5% of Stonegate Investment Group LLC’s investment portfolio, making the stock its 24th biggest position. Stonegate Investment Group LLC owned approximately 0.12% of Kenvue worth $47,906,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of KVUE. Vanguard Group Inc. purchased a new stake in Kenvue in the 3rd quarter valued at approximately $2,944,816,000. FMR LLC lifted its stake in Kenvue by 572.1% in the 3rd quarter. FMR LLC now owns 89,182,980 shares of the company’s stock valued at $1,790,794,000 after buying an additional 75,913,107 shares in the last quarter. Wellington Management Group LLP lifted its stake in Kenvue by 576.1% in the 3rd quarter. Wellington Management Group LLP now owns 71,686,830 shares of the company’s stock valued at $1,439,472,000 after buying an additional 61,084,123 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its stake in Kenvue by 227.7% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 61,091,189 shares of the company’s stock valued at $1,226,711,000 after buying an additional 42,449,470 shares in the last quarter. Finally, Morgan Stanley lifted its stake in Kenvue by 4,057.4% in the 3rd quarter. Morgan Stanley now owns 31,162,614 shares of the company’s stock valued at $625,745,000 after buying an additional 30,413,040 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Down 1.3 %

NYSE KVUE traded down $0.24 during trading hours on Tuesday, hitting $18.82. The company had a trading volume of 26,741,112 shares, compared to its average volume of 16,772,949. Kenvue Inc. has a fifty-two week low of $17.82 and a fifty-two week high of $27.80. The company has a market capitalization of $36.03 billion and a price-to-earnings ratio of 15.30. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.12 and a quick ratio of 0.78. The firm’s 50 day moving average is $19.83 and its 200 day moving average is $20.13.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Thursday, February 8th. The company reported $0.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.28 by $0.03. Kenvue had a return on equity of 15.62% and a net margin of 9.87%. The firm had revenue of $3.67 billion during the quarter, compared to the consensus estimate of $3.78 billion. Kenvue’s quarterly revenue was down 2.7% on a year-over-year basis. Sell-side analysts anticipate that Kenvue Inc. will post 1.15 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, May 22nd. Stockholders of record on Wednesday, May 8th will be paid a dividend of $0.20 per share. The ex-dividend date is Tuesday, May 7th. This represents a $0.80 annualized dividend and a dividend yield of 4.25%. Kenvue’s dividend payout ratio is presently 65.04%.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on KVUE shares. Sanford C. Bernstein started coverage on Kenvue in a research note on Thursday, April 11th. They issued an “underperform” rating and a $18.00 target price on the stock. JPMorgan Chase & Co. reduced their price target on Kenvue from $25.00 to $24.00 and set an “overweight” rating on the stock in a research note on Friday, February 9th. William Blair started coverage on Kenvue in a research note on Wednesday, April 3rd. They set a “market perform” rating on the stock. The Goldman Sachs Group started coverage on Kenvue in a research note on Friday, March 1st. They set a “neutral” rating and a $20.00 price target on the stock. Finally, Royal Bank of Canada reduced their price target on Kenvue from $25.00 to $24.00 and set an “outperform” rating on the stock in a research note on Friday, February 9th. One analyst has rated the stock with a sell rating, eight have given a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $24.85.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.